URGENT UPDATE: Nearly 581,000 bottles of blood pressure medication have been recalled due to elevated levels of a potentially cancer-causing chemical. Teva Pharmaceuticals initiated this voluntary recall for prazosin hydrochloride capsules on October 7, 2023, following alarming test results.
The U.S. Food and Drug Administration (FDA) classified this recall as a Class II risk on October 24, indicating that exposure to these capsules “may cause temporary or medically reversible adverse health consequences.” Patients are urged to act immediately.
This recall affects three dosage strengths of the medication distributed nationwide, primarily used for treating high blood pressure and prostate conditions. Additionally, it is sometimes prescribed off-label for managing post-traumatic stress disorder (PTSD) symptoms.
Tests revealed that the recalled capsules contain elevated levels of N-nitroso prazosin impurity, prompting this urgent action. The specific details of the recall include:
- 1 mg capsules: 181,659 bottles (NDC 0093-4067-01 and 0093-4067-10) with lot numbers 3010544A and 3010545A, expiring in October 2025.
- 2 mg capsules: 291,512 bottles (NDC 0093-4068-01 and 0093-4068-10) across multiple lot numbers, with expiration dates from October 2025 through July 2026.
- 5 mg capsules: 107,673 bottles (NDC 0093-4069-01, 0093-4069-52, and 0093-4069-05) across various lot numbers, expiring in 2026.
Healthcare professionals are strongly advising patients currently taking the recalled medication to consult with their providers immediately. Discontinuing blood pressure medication suddenly can pose serious health risks.
“Patients should reach out to their healthcare provider as soon as possible to assess their situation,” stated a representative from Teva Pharmaceuticals.
Teva has begun notifying customers by letter, and the recall process remains ongoing. Patients with questions regarding their medication are encouraged to contact their pharmacist or healthcare provider to determine whether their supply is affected and to explore alternative treatment options.
This recall highlights the critical importance of monitoring medication safety. As developments unfold, patients and healthcare providers must remain vigilant regarding their treatments.
Stay tuned for more updates as this situation develops.
